Nifuratel
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Nifuratel is a nitrofuran derivative indicated in the treatment of leucorrhea, vulvovaginal infections, and urinary tract infections.
- Generic Name
- Nifuratel
- DrugBank Accession Number
- DB13724
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 285.27
Monoisotopic: 285.04194164 - Chemical Formula
- C10H11N3O5S
- Synonyms
- Nifuratel
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Bacterial vaginitis Combination Product in combination with: Nystatin (DB00646) •••••••••••• Treatment of Fungal vaginal infections •••••••••••• Treatment of Trichomonal vaginitis •••••••••••• Used in combination to treat Trichomonal vaginitis Combination Product in combination with: Nystatin (DB00646) •••••••••••• Used in combination to treat Vaginal candidiasis Combination Product in combination with: Nystatin (DB00646) •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Nifuratel. Dicoumarol The therapeutic efficacy of Dicoumarol can be increased when used in combination with Nifuratel. Fluindione The therapeutic efficacy of Fluindione can be increased when used in combination with Nifuratel. Phenindione The therapeutic efficacy of Phenindione can be increased when used in combination with Nifuratel. Phenprocoumon The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Nifuratel. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image INIMUR COMPLEX Nifuratel (500 MG) + Nystatin (200000 IU) Capsule Vaginal Polichem S.R.L. 2014-07-08 Not applicable Italy INIMUR COMPLEX Nifuratel (10 g/100g) + Nystatin (4000000 IU) Cream Vaginal Polichem S.R.L. 2014-07-08 Not applicable Italy INIMUR COMPLEX Nifuratel (500 MG) + Nystatin (200000 IU) Capsule Vaginal Polichem S.R.L. 2014-07-08 Not applicable Italy MACMIROR COMPLEX Nifuratel (500 MG) + Nystatin (200000 IU) Insert Vaginal Gmm Farma S.R.L. 2020-02-15 2022-10-29 Italy MACMIROR® COMPLEX Nifuratel (500 mg) + Nystatin (200000 IU) Capsule Vaginal DOPPEL FARMACEUTICI S.R.L. 2010-02-01 Not applicable Colombia
Categories
- ATC Codes
- G01AX05 — Nifuratel
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Furans
- Sub Class
- Nitrofurans
- Direct Parent
- Nitrofurans
- Alternative Parents
- Nitroaromatic compounds / Oxazolidinones / Heteroaromatic compounds / Organic carbonic acids and derivatives / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Dialkylthioethers / Azacyclic compounds show 5 more
- Substituents
- 2-nitrofuran / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Carbonic acid derivative / Carbonyl group / Dialkylthioether / Heteroaromatic compound / Hydrocarbon derivative show 17 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- U60U6P08SP
- CAS number
- 4936-47-4
- InChI Key
- SRQKTCXJCCHINN-NYYWCZLTSA-N
- InChI
- InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+
- IUPAC Name
- 5-[(methylsulfanyl)methyl]-3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
- SMILES
- CSCC1CN(\N=C\C2=CC=C(O2)[N+]([O-])=O)C(=O)O1
References
- General References
- External Links
- ChemSpider
- 4938579
- 7419
- ChEBI
- 135180
- ChEMBL
- CHEMBL514315
- Wikipedia
- Nifuratel
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Vaginal Cream Vaginal Insert Vaginal Insert Vaginal 500 mg Suppository Vaginal Cream Vaginal 10 % Tablet Vaginal 250 MG Tablet, coated Oral 200 MG Capsule Vaginal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.109 mg/mL ALOGPS logP 0.95 ALOGPS logP 1.72 Chemaxon logS -3.4 ALOGPS pKa (Strongest Basic) -2.1 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 98.18 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 66.88 m3·mol-1 Chemaxon Polarizability 27.28 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-01p2-9230000000-6b014b7e904925e8ceda Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 159.28606 predictedDeepCCS 1.0 (2019) [M+H]+ 162.54613 predictedDeepCCS 1.0 (2019) [M+Na]+ 170.60045 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:47 / Updated at May 22, 2021 06:01